From: Low expression of ACLY associates with favorable prognosis in acute myeloid leukemia
Variables | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|
P value | HR (95% CI) | P value | HR (95% CI) | |
ACLY expression (high vs. low) | 0.001 | 2.19 (1.38, 3.475) | 0.029 | 1.805 (1.062, 3.068) |
Age | < 0.001 | 1.007 (1.004, 1.011) | 0.009 | 1.006 (1.001, 1.01) |
WBC | < 0.001 | 1.005 (1.003, 1.007) | < 0.001 | 1.004 (1.002, 1.006) |
Cytogenetic risks | ||||
Intermediate vs. favorable | 0.003 | 3.811 (1.556, 9.337) | 0.027 | 3.748 (1.164, 12.069) |
Poor vs. favorable | < 0.001 | 8.539 (3.247, 22.454) | 0.001 | 7.978 (2.34, 27.197) |
Gene mutations (mutation vs. wild-type) | ||||
FLT3-ITD | 0.022 | 1.66(1.076, 2.56) | 0.007 | 1.969(1.208,3.21) |
NPM1 | 0.051 | 1.434(0.998,2.061) | 0.812 | 1.05(0.702,1.571) |
CEBPADM | 0.022 | 0.385(0.169,0.874) | 0.040 | 0.409(0.175,0.960) |
DNMT3A | 0.001 | 2.474(1.483,4.125) | 0.022 | 1.98(1.105,3.546) |
Treatmenta | ||||
HAA vs. DA | 0.001 | 0.503 (0.335, 0.756) | 0.007 | 0.536 (0.341, 0.842) |
IA vs. DA | 0.003 | 0.567 (0.391, 0.824) | 0.002 | 0.48 (0.304, 0.756) |